CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

被引:5
|
作者
Yi, Yonglin [1 ]
Qiu, Zhengang [2 ]
Yao, Zifu [1 ,3 ]
Lin, Anqi [1 ]
Qin, Yimin [1 ]
Sha, Ruizhan [1 ]
Wei, Ting [1 ]
Wang, Yanru [1 ]
Cheng, Quan [4 ]
Zhang, Jian [1 ]
Luo, Peng [1 ]
Shen, Weitao [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China
[2] Gannan Med Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China
[3] Southern Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[4] Ctr South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China
基金
中国国家自然科学基金;
关键词
small cell lung cancer; CAMSAP1; platinum-based chemotherapy; drug sensitivity; biomarker; ACTIVATED PROTEIN-KINASE; TGF-BETA; B-CELLS; EXPRESSION; CHEMORESISTANCE; IMMUNOTHERAPY; SURVIVAL; FAMILY; MECHANISMS; MANAGEMENT;
D O I
10.3389/fcell.2021.770811
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
    Hirotsugu Kenmotsu
    Tateaki Naito
    Keita Mori
    Ryo Ko
    Akira Ono
    Kazushige Wakuda
    Hisao Imai
    Tetsuhiko Taira
    Haruyasu Murakami
    Masahiro Endo
    Toshiaki Takahashi
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 521 - 526
  • [32] Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy
    Jin, Shi
    Cao, Shoubo
    Xu, Shanqi
    Wang, Chunyan
    Meng, Qingwei
    Yu, Yan
    CLINICAL RESPIRATORY JOURNAL, 2018, 12 (09): : 2433 - 2440
  • [33] INTRINSIC AND ACQUIRED RESISTANCE PATTERNS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY
    Stewart, David J.
    Saintigny, Pierre
    Lu, Charles
    Goss, Glenwood
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S862 - S863
  • [34] Curative efficacy might be an early predictor of prognosis in patients with small cell lung cancer treated with 2 cycles of platinum-based first-line chemotherapy
    Zhu, Kaibo
    Jiang, Minlin
    Xu, Yi
    Chen, Peixin
    Wang, Hao
    Yu, Jia
    Zhu, Jun
    Zhao, Wencheng
    Meng, Die
    He, Yayi
    JOURNAL OF THORACIC DISEASE, 2021, 13 (02) : 1205 - 1214
  • [35] NANOG Predicts Poor Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Lee, Seung Hyeun
    Park, Myung Jae
    Park, So Young
    In, Kwang Ho
    Kim, Chul Hwan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S959 - S960
  • [36] Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Mori, Keita
    Ko, Ryo
    Ono, Akira
    Wakuda, Kazushige
    Imai, Hisao
    Taira, Tetsuhiko
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Toshiaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 521 - 526
  • [37] Chemotherapy-induced leukopenia as a prognostic factor in patients with metastatic non-small cell lung cancer treated with platinum-based chemotherapy
    Huang, Aimi
    Ma, Meili
    Jin, Bo
    Han, Baohui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 5241 - 5248
  • [38] Association of variations in the Fanconi anemia complementation group and prognosis in Non-small cell lung cancer patients with Platinum-based chemotherapy
    Mo, Jun-Luan
    Liu, Jia-Si
    Xiao, Qi
    Hong, Wen-Xu
    Yin, Ji-Ye
    Chen, Juan
    Liu, Zhao-Qian
    GENE, 2022, 825
  • [39] Pretreatment Inflammatory Indexes are Associated with Response to First-Line Platinum-Based Chemotherapy and Prognosis of Small Cell Lung Cancer Patients
    Inanc, Mevlude
    Bozkurt, Oktay
    Ocak Duran, Ayse
    Ozkan, Metin
    Altinbas, Mustafa
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2019, 29 (02): : 79 - 87
  • [40] Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients
    陈进娜
    ChinaMedicalAbstracts(InternalMedicine), 2019, 36 (02) : 102 - 103